Skip to main content

Table 1 Clinicopathological parameters in patients with breast cancer

From: Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity

   H3K9me3     H4K20me3  
  score 0 1+ 2+    score 0 1+ 2+  
  N = 71 25 22 24    N = 93 36 23 34  
   35.2 31.0 33.8 (%)    38.7 24.7 36.6 (%)
  N     P*   N     P*
Pathological classification 71     0.503 Pathological classification 93     0.478
DCIS, microinvasive   1 5 3   DCIS, microinvasive   1 3 4  
idc, pap   9 9 7   idc, pap   11 8 10  
idc, sol   4 3 3   idc, sol   10 3 3  
idc, sci   8 2 6   idc, sci   8 4 10  
special type   3 3 5   special type   6 5 7  
Lymph node metastasis 64     0.493 Lymph node metastasis 83     0.060
0-3   20 15 16   0-3   22 19 25  
3<   3 4 6   3<   11 3 3  
Nuclear grade 70     0.838 Nuclear grade 91     0.022
1   12 12 9   1   8 10 21  
2   4 4 4   2   7 4 6  
3   9 6 10   3   19 9 7  
ER 70     0.707 ER 93     0.027
Negative   9 9 11   Negative   21 10 9  
Positive   16 13 12   Positive   15 13 25  
PgR 68     0.590 PgR 91     0.019
Negative   10 9 12   Negative   21 13 10  
Positive   14 13 10   Positive   13 10 24  
HER2 71     0.580 HER2 93     0.082
Negative (0/1)   20 15 19   Negative (0/1)   29 14 29  
Positive (2/3)   5 7 5   Positive (2/3)   7 9 5  
Intrinsic subtype 69     0.462 Intrinsic subtype 91     0.002
Luminal   18 14 12   Luminal   14 14 28  
Non-luminal   7 8 10   Non-luminal   20 9 6  
MIB-1 index 69     0.482 MIB-1 index 91     0.001
<30   14 9 9   <30   9 8 24  
30   11 13 13   30   25 15 10  
  1. *Chi-squared test. Bold indicates values that are statistically significant. DCIS, ductal carcinoma in situ; idc, invasive ductal carcinoma; pap, papillotubular carcinoma; sol, solid-tubular carcinoma; sci, scirrhous carcinoma; ER, estrogen receptor; PgR, progesterone receptor; luminal, ER positive and/or PgR positive.